ESR1 mutation

"Virginia Kaklamani, MD @VKaklamani @UTHealthsaMDA discusses new data from #ASCO23 FDA-approved #Elacestrant for #breastcancer with ESR1-mutations. The EMERALD study results, announced by the #Menarini @Stemline Therapeutics, show PFS benefits. 🔬[video] https://t.co/9fioU5hFAU" (@oncologytube)

2/6 #TumorBoardTuesday ThursCase🎀 Take🏠msgs: #metastatic HR+ #breastcancer ✅ NGS is 🗝️ in ER+ mBC on CDK4/6i ✅ ESR1 mut➡️Elacestrant ✅ No ESR1 mutation, but PIK3CA mut, consider 🎯tx, beware side effects 📚Here’s @ilanaschlam @drsarahsam’s thread https://t.co/DcA8w8ofI9 (@JohnEbbenMDPhD)

11/17 #TumorBoardTuesday #SABCS22 ✨EMERALD✨ post hoc analysis: ❗without ESR1 mutations + PD <6mos on CDK4/6 inhibitor = elacestrant ⬆️ PFS (5.3 vs 1.9m) ❗without ESR1 mutations + PD >6mos on CDK4/6 inhibitor = elacestrant ↔️ PFS (1.9 vs 2 m) #ASCO23 #VirginiaKalkamani (@IlanaSchlam)

Findings from a subgroup analysis of the phase 3 EMERALD trial demonstrated elacestrant elicited prolonged PFS vs SOC in ER+, HER2– non-detected ESR1 mutated breast cancer who experienced disease progression. @VKaklamani #ASCO23 #bcsm https://t.co/lPcacbcFRo (@OncLive)

Check out Dr. Virginia Kaklamani @VKaklamani @UTHealthSAMDA discussing #ASCO23 Oral #Elacestrant vs. SOC in ER+/HER2- Advanced or #mBC w/o Detectable #ESR1 Mutation (EMERALD) - Subgroup Analysis by Prior Duration of CDK4/6i + ET #bcsm #breastcancer #cdk46 https://t.co/SDTuK9Jxot (@Sameh_VuMedi)

Findings from a subgroup analysis of the phase 3 EMERALD trial demonstrated elacestrant elicited prolonged PFS vs SOC in ER+, HER2– non-detected ESR1 mutated breast cancer who experienced disease progression. @VKaklamani @ASCO #ASCO23 #bcsm https://t.co/IDnlmEDmWA (@OncLive)

#ESR1 mutational lanscape and impact of co-existing resistance variants on clinical outcomes in patients with #metastaticbreastcancer @ArielleMedford @dradityabardia @MCristofanill @harvardmed @MassGenBrigham @WCM_MeyerCancer @NorthwesternMed @WUDeptMedicine @ConquerCancerFd (@CtcLaboratory)

ELAINE-2 study (N 29), all post CDK4/6i, ESR1-mutated selected HR+HER2- #bcsm lasofoxifene + abema ORR 55.6%, mPFS 56 weeks 💪. ELAINE 3 (NCT05696626) will compare LAS/Abema with Fulv/Abema. Watch out for dvt risk (N 3/29). #ASCO23 #postcdk46 (@antgiorda)

Nice outline of ESR1 mutations in #breastcancer by @CHernandoM. #ASCO23 #bcsm (@drteplinsky)

@ASCO recommends testing for #ESR1 mutations in ER+/HER2- MBC recurrent or progressed on ET. https://t.co/CiHKBfAE9i @ColumbiaRadOnc/@columbiacancer recently showed ESR1 mutations in 14.3% of HR+ MBC and 12% of pre-treated HR+ primary BC. (@RadOncConnor)

Guideline Update Provides New Testing & Tx Recx for Pts w/ ER-Positive, HER2-Negative Met Breast Cancer w/ ESR1 Mutations [May 17-18, 2023] @ASCO Daily News - https://t.co/3ZVrEkQEN5 @DrHBurstein et al. @JCO_ASCO https://t.co/68e7D0CSgU #bcsm #PrecisionMedicine #LiquidBiopsy (@mtmdphd)

#ASCODailyNews highlights our rapid guideline update that provides new testing/treatment recommendations for pts w/ ER+, HER2- metastatic #breastcancer w/ ESR1 mutations: https://t.co/YlrRLXdh1l @AngieDemichele #bcsm (@ASCO)

🚨 ASCO Guideline update ➡️ Test for ESR1 mutation either by ctDNA or tumor tissue for ER+ve mBC who progressed on ET/CDK inhibitors following evidence from EMARELD trial. @OncoAlert #MedTwitter @BreastCancerNow @Cancer_Free_IND @AggregoOncology @JCO_ASCO https://t.co/FaAsskw7gT (@saadvikdr)

Testing for ESR1 Mutations to Guide Therapy for HR–Positive, HER2–Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update 📌It was recommended to perform routine ESR1 test after ET (+/- CDK). @ASCO @JCO_ASCO @OncoAlert https://t.co/YuQTYHOhNj (@dr_yakupergun)

Significant impact for CDK4/6i BP, especially in patients with ESR1 mutations. @LGerratana ➡️ https://t.co/l78UJ9OnDB #bcsm (@JCOPO_ASCO)

Out today on ⁦@JCOPO_ASCO⁩ CDK4/6i Beyond Progression impacts PFS and OS, especially in #ESR1 mutated #MBC. ESR1 has a negative impact in the upfront setting due to the AI backbone, whereas RB1 negatively affect CDK4/6i BP #ctDNA #LiquidBiopsy #bcsm https://t.co/TpNGku4c4A (@LGerratana)

MSK Discovery of ESR1 Gene Mutation Leads to Approval of Breast Cancer Drug Elacestrant https://t.co/ah7q7hoJXx (@weldeiry)

Dr Erica Mayer (@elmayermd) is a co-investigator on SERENA-6 (NCT04964934), an ongoing randomized, double-blind, phase III trial of camizestrant + CDK4/6i in ESR1-mutant HR+/HER2-negative advanced breast cancer during first-line treatment. Trial protocol: https://t.co/bIeMClWmjx (@DFCI_BreastOnc)

Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line trea… https://t.co/kQji0I64pj Very nice ongoing study, reminiscent of the PADA 1 trial, but with a better (oral) SERD. I believe, however, that an arm is missing.... (@FilippoMontemu1)

Sorry, the approval doesn’t use “locally.” “postmenopausal women or adult men, w ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer w disease progression following at least 1 line of endocrine therapy.” These “advanced” definitions are still confusing though! (@itsnot_pink)

21/24 #TumorBoardTuesday #BreastCancer ✨EMERALD✨ 🎉 Based on data, elacestrant was approved on Jan 27, 2023 for treatment of patients with ESR1-mutant HR+ breast cancer who have progressed to at least 1L of endocrine treatment 📚 https://t.co/DY4VIO4Smo (@PTarantinoMD)

20/24 #TumorBoardTuesday ✨EMERALD✨ 📍phase 3 📍oral SERD elacestrant outperformed SoC endocrine treatment (AI or Fulvestrant) in endocrine-refractory MBC 📍benefit enhanced in ESR1-mutant #BreastCancer & in patients who have received > 12 months of prior CDK4/6 inhibitors (@PTarantinoMD)

A lot going on for ESR1 mutant metastatic breast cancer, with several novel SERDS (+ some “unconventional” ET agents) demonstrating clinical benefits recently (@PTarantinoMD)

Hear ye, hear ye! Important Estrogen receptor degraded approved for ESR1 mutated breast cancers. FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer | FDA https://t.co/LYNgE4gNJT (@Dr_R_Kurzrock)

FDA Approves Elacestrant for ER+/HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer https://t.co/71FQBY1D4U via @onclive (@DrFaridSaleh)

Elacestrant (345 mg taken orally with food once daily) approved for ER+ve, HER2-ve, ESR1-mutated advanced or metastatic breast cancer based on EMERALD trial https://t.co/0ZF6hLUvgu (@drkpavithran)

FDA approved elacestrant for ER+/HER2- ESR1mt metastatic breast cancer. We recently reviewed the frequency of ESR1 mutations in primary and metastatic breast cancer. https://t.co/SIVBMBSA1i (@RadOncConnor)

First oral SERD elacestrant (Orserdu) approved by ⁦@FDAOncology⁩ for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer ⁦ https://t.co/ZzTSAkpyPd (@cancermedic)

JUST OUT @US_FDA 🇺🇸Approves elacestrant in postmenopausal women/adult men w/ER➕HER2➖ESR1🧬mutated advanced or metastatic #BreastCancer w/disease progression following at least 1️⃣line ET Decision based on Efficacy in EMERALD💎 @OncoAlert 🚨@FDAOncology https://t.co/B0cTY6nN11 (@weoncologists)

The oral SERD Elacestrant is now approved for ESR1 mutated HR+/HER2- advanced #breastcancer after one line of ET, based on the results of the #EMERALD study🎯 One more option for our patients! (@ElisaAgostinett)

Should people with HR+, HER2- MBC be tested for ESR1 mutation on diagnosis, or only after progression on endocrine therapy? EMERALD was a fairly small study, but do you know if there was any analysis of which ESR1 mutations most people had? (@stage4kelly)

@FDAOncology just approved elacestrant for ESR1-mutant breast cancer based on Phase III #EMERALD Trial. Read our recent paper where we review the frequency of #ESR1 mutations in primary and metastatic breast cancer. @ASCO @AACR https://t.co/xujVr15iG4 (@RadOncConnor)

FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer https://t.co/edGR6cR3Sk (@MCristofanill)

So the day we’ve all been talking about has arrived. The oral SERDs are finally here! Are they going to be all they’ve hyped up to be??? How does everyone feel about the restriction to ESR1 mutation carriers??? #bcsm (@Dr_RShatsky)

FDA Approves Elacestrant for ER+/HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer https://t.co/qnNCx6fZmH via @onclive (@DrBonillaOnc)

First oral #SERD approved for HR+ metastatic #bcsm w/ ESR1 mutation- welcome #elacestrant. Much more work being done with this class of compounds including: 1) earlier settings, 2) combinations, 3) additional novel oral SERDs coming, 4) benefit in all comers. @OncoAlert (@ErikaHamilton9)

Great new option for patients with HR+, HER2- #mbc with progression on CDK4/6 inhibitor AND an ESR1 mutation! Preferred at least 12 months on a CDK4/6 inhibitor. Congratulations @dradityabardia and EMERALD investigators. Biomarker specific coprimary endpoint for the win! #bcsm (@drsarahsam)

In our recent paper we review the frequency of #ESR1 mutations in primary and metastatic breast cancer. https://t.co/xujVr15iG4 (@RadOncConnor)

Hot off the presses: FIRST ORAL SERD APPROVED FOR HR+/HER2- metastatic breast cancer! Elacestrant (Orserdu) approved for ESR1 mutated HR+ MBC after one line of ET. More options for our patients, one more step forward! (@hoperugo)

FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer ⁦@OncoAlert⁩ ⁦@FDAOncology⁩ ⁦@ASCO⁩ (@jamecancerdoc)

Elacestrant (Orserdu) FDA approved for ER+ HER2- metastatic #breastcancer with #ESR1 mutation @OncoAlert #bcsm https://t.co/FV8dsW3Nxc (@JAMouabbi)

Palbociclib rechallenge for HR–positive/HER-negative advanced breast cancer -CBR 34.4% and median PFS- 2.6 months; low Rb score, high cyclin E1 score, ESR1 mutation - predicted worse outcome - BioPER Trial https://t.co/zbYK8JbdwE (@drkpavithran)